tradingkey.logo

Lipocine to change FDA labeling for testosterone products

ReutersMar 12, 2025 1:59 PM

- Lipocine Inc LPCN.O:

  • LIPOCINE ANNOUNCES FDA LABELING CHANGES FOR TESTOSTERONE PRODUCTS

  • LIPOCINE: FDA RECOMMENDED BOXED WARNING RELATED TO INCREASED RISK OF ADVERSE CARDIOVASCULAR OUTCOMES BE REMOVED FROM LABELS OF TESTOSTERONE PRODUCTS

  • LIPOCINE: FDA IS ALSO REQUIRING ALL LABELS TO INCLUDE PRODUCT-SPECIFIC INFORMATION ON INCREASED BLOOD PRESSURE FOR TESTOSTERONE PRODUCTS

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI